Incidence of autoimmune pulmonary alveolar proteinosis estimated using Poisson distribution

被引:19
作者
Kitamura, Nobutaka [1 ]
Ohkouchi, Shinya [2 ,3 ]
Tazawa, Ryushi [4 ]
Ishii, Haruyuki [5 ]
Takada, Toshinori [6 ]
Sakagami, Takuro [7 ]
Tanaka, Takahiro [1 ]
Nakata, Koh [1 ]
机构
[1] Niigata Univ, Med & Dent Hosp, Clin & Translat Res Ctr, 1-754 Asahimachi Dori, Niigata 9518520, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Miyagi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Occupat Hlth, Sendai, Miyagi, Japan
[4] Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata, Japan
[5] Kyorin Univ, Dept Resp Med, Sch Med, Tokyo, Japan
[6] Niigata Univ, Med & Dent Hosp, Uonuma Inst Community Med, Minami Uonuma, Japan
[7] Kumamoto Univ Hosp, Dept Pulm Med, Kumamoto, Japan
关键词
MEAN SURVIVAL-TIME; GM-CSF AUTOANTIBODY; PREVALENCE; DIAGNOSIS; DISEASE; RATIO;
D O I
10.1183/23120541.00190-2018
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The incidence and prevalence of autoimmune pulmonary alveolar proteinosis in Japan were previously estimated to be 0.49 and 6.2 per million, respectively. Thereafter, an increase in serological diagnosis forced a re-estimation of the incidence based on more contemporaneous data using more robust methods. Sera of 702 patients were positive for granulocyte-macrophage colony-stimulating factor autoantibody during the 2006-2016 period (group A). Of these patients, 43 were actively surveyed in Niigata prefecture (group B) for estimation of the incidence. To estimate the survival period, 103 patients (group C) were investigated retrospectively for the 1999-2017 period using restricted mean survival time. In group A, the number of patients diagnosed in each prefecture was closely correlated with the corresponding population, indicating no regional integration of onset. In group B, a total of 43 patients were diagnosed, the annual number followed a Poisson distribution and the incidence was thus estimated to be 1.65 per million. In group C, the retrospective cohort study revealed the mean survival period to be 16.1 years. Taken together, the prevalence was estimated to be 26.6 per million, indicating that the previous data for incidence and prevalence was an underestimation.
引用
收藏
页数:10
相关论文
共 28 条
[1]  
BAILAR JC, 1964, BIOMETRICS, V20, P639
[2]   Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community [J].
Bambha, K ;
Kim, WR ;
Talwalkar, J ;
Torgerson, H ;
Benson, JT ;
Therneau, TM ;
Loftus, EV ;
Yawn, BP ;
Dickson, ER ;
Melton, LJ .
GASTROENTEROLOGY, 2003, 125 (05) :1364-1369
[3]  
Ben-Dov I, 1999, ISRAEL MED ASSOC J, V1, P75
[4]   An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use [J].
Calkins, Keri L. ;
Canan, Chelsea E. ;
Moore, Richard D. ;
Lesko, Catherine R. ;
Lau, Bryan .
BMC MEDICAL RESEARCH METHODOLOGY, 2018, 18
[5]   Population-based incidence and prevalence of facioscapulohumeral dystrophy [J].
Deenen, Johanna C. W. ;
Arnts, Hisse ;
van der Maarel, Silvere M. ;
Padberg, George W. ;
Verschuuren, Jan J. G. M. ;
Bakker, Egbert ;
Weinreich, Stephanie S. ;
Verbeek, Andre L. M. ;
van Engelen, Baziel G. M. .
NEUROLOGY, 2014, 83 (12) :1056-1059
[6]   BASIC MODELS FOR DISEASE OCCURRENCE IN EPIDEMIOLOGY [J].
FLANDERS, WD ;
KLEINBAUM, DG .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (01) :1-7
[7]  
Fletcher RH, 1996, CLIN EPIDEMIOLOGY ES, P84
[8]   PREVALENCE, INCIDENCE AND DURATION [J].
FREEMAN, J ;
HUTCHISON, GB .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1980, 112 (05) :707-723
[9]   Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy [J].
Guidetti, D ;
Sabadini, R ;
Bondavalli, M ;
Cavaletti, S ;
Lodesani, M ;
Mantegazza, R ;
Cosi, F .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1998, 14 (04) :381-387
[10]   PRECISION OF INCIDENCE PREDICTIONS BASED ON POISSON DISTRIBUTED OBSERVATIONS [J].
HAKULINEN, T ;
DYBA, T .
STATISTICS IN MEDICINE, 1994, 13 (15) :1513-1523